|
gptkbp:instanceOf
|
gptkb:drug
gptkb:immunosuppressive_agent
gptkb:monoclonal_antibody
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L04AB04
|
|
gptkbp:biosimilar
|
gptkb:Cyltezo
gptkb:Abrilada
gptkb:Amjevita
gptkb:Hadlima
gptkb:Hyrimoz
gptkb:Idacio
gptkb:Simlandi
gptkb:Yuflyma
Halimatoz
|
|
gptkbp:brand
|
gptkb:Humira
|
|
gptkbp:CASNumber
|
331731-18-1
|
|
gptkbp:developedBy
|
gptkb:AbbVie
|
|
gptkbp:firstBiosimilarApproved
|
2018 (Europe)
|
|
gptkbp:hasMolecularFormula
|
C6428H9912N1694O1987S46
|
|
gptkbp:highestGrossingDrug
|
2012-2022
|
|
gptkbp:indication
|
gptkb:juvenile_idiopathic_arthritis
gptkb:Crohn's_disease
gptkb:psoriatic_arthritis
ulcerative colitis
rheumatoid arthritis
uveitis
ankylosing spondylitis
plaque psoriasis
hidradenitis suppurativa
|
|
gptkbp:KEGGID
|
D02597
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to TNF-α and inhibits its activity
|
|
gptkbp:patentExpiredEU
|
2018
|
|
gptkbp:patentExpiredUS
|
2023
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201585
DB00051
|
|
gptkbp:revenue
|
over $20 billion (2021)
|
|
gptkbp:riskFactor
|
tuberculosis
malignancy
serious infections
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
nausea
headache
injection site reaction
rash
upper respiratory tract infection
|
|
gptkbp:target
|
gptkb:tumor_necrosis_factor_alpha_(TNF-α)
|
|
gptkbp:UNII
|
FYS6T7F842
|
|
gptkbp:bfsParent
|
gptkb:ABBV
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
adalimumab (Humira)
|